MYLS22

Research use only, not for human use.

MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor.

MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor. MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression.

Western Blot Analysis Cell Line:MLE12 cells Concentration:10 nM Incubation Time:30 min Result:Increased the phosphorylation levels of RIPK3 and MLKL protein.

Animal Model:LPS‐induced ALI miceDosage:12.5 mg/kg Administration:i.p., 2 days Result:Increased lung inflammatory score, Tnf‐α and pro‐Il‐1β mRNA expression, and total IL‐1β or IL‐1β p17 protein expression.Increased the levels of RIPK3, MLKL protein, and their phosphorylation.Decreased the levels of SPC protein.

——

Others

Other Targets

OPA1

——

——

306959-01-3

443.52

C??H??N?O?S

>98% (HPLC)

DMSO : 50 mg/mL (112.73 mM; ultrasonic and warming and heat to 60°C)

——

——

(-20℃)

With Ice Pack

≥ 2 years